Skip to main content
LXRX
NASDAQ Life Sciences

Lexicon Q3 Revenue $11.3M; SONATA-HCM Fully Enrolled, Data Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.61
Mkt Cap
$658.535M
52W Low
$1.1
52W High
$2.68
52W Position info
46% above low
Off High info
40% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LXRX sits 46% above its 52-week low of $1.1.

Summary

Lexicon posted $11.3M in Q3 revenue, down from $14.2M a year ago, but fully enrolled its 542-patient SONATA-HCM Phase 3 and cleared the safety bar for a ZYNQUISTA NDA resubmission — both with Q1 2027 milestones. Cash of $183.2M covers the $14.0M quarterly net loss through those readouts.


Key Events · Earnings and Guidance · LXRX

  • Q3 Revenue Falls to $11.3M

    Total revenue of $11.3M versus $14.2M a year ago, driven by $10.0M of Novo milestone revenue versus $13.2M in the prior-year quarter; INPEFA net sales were $1.2M.

  • SONATA-HCM Overenrolls at 542 Patients

    The pivotal Phase 3 in obstructive and non-obstructive HCM enrolled 542 patients, substantially exceeding plan, with topline data expected in Q1 2027.

  • ZYNQUISTA NDA Resubmission Set for Q1 2027

    The STENO1 investigator-initiated study met the FDA-agreed patient exposure and safety requirements, with low DKA rates comparable to standard of care; NDA resubmission anticipated in Q1 2027.

  • Cash of $183.2M Funds Both Readouts

    Cash and investments rose to $183.2M at September 30, 2026 from $125.2M at December 31, 2025, aided by $96.2M of net stock-sale proceeds in February 2026, against a $14.0M Q3 net loss.


Analysis · LXRX · Life Sciences

Revenue fell to $11.3M from $14.2M a year ago, as the prior-year quarter carried $13.2M of Novo licensing revenue versus $10.0M this quarter, while INPEFA product sales were just $1.2M. The more consequential news is operational: SONATA-HCM enrolled 542 patients, well above plan, with topline data now expected in Q1 2027, and the STENO1 safety data clears the FDA-agreed bar for a ZYNQUISTA NDA resubmission also targeted for Q1 2027. With $183.2M in cash and investments against a $14.0M quarterly net loss, the company is funded through both readouts without an immediate raise. Two binary catalysts land in the same quarter next year, which is what makes this quarter's report matter beyond the top line.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LXRX was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $658.5M. The 52-week trading range was $1.10 to $2.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LXRX - Latest Insights

LXRX
Nov 05, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.74 info
Change: +$0.1269 (+8%) info
Market Cap: $765.803M info
LXRX
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.74 info
Change: +$0.130 (+8%) info
Market Cap: $765.803M info
LXRX
Aug 31, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.74 info
Change: -$0.560 (-24%) info
Market Cap: $765.803M info
LXRX
Aug 24, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $1.74 info
Change: -$0.640 (-27%) info
Market Cap: $765.803M info
LXRX
Aug 06, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.74 info
Change: -$0.210 (-11%) info
Market Cap: $765.803M info